- Trials with a EudraCT protocol (1,417)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,417 result(s) found for: slovak republic.
Displaying page 1 of 71.
EudraCT Number: 2004-004083-77 | Sponsor Protocol Number: NO 002 CS 001 | Start Date*: 2004-12-13 |
Sponsor Name:Disphar International B.V. | ||
Full Title: A Randomised, International, Multicenter Study to assess the Efficacy and Safety of Mesalazine EC tablets 500 mg (4.5g/daily) and Salofalk® tablets 500 mg (4.5 g/daily) in the Treatment of Moderate... | ||
Medical condition: Moderate active Crohn disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005367-27 | Sponsor Protocol Number: 10-PN-PD-DIT-087 | Start Date*: 2013-02-12 |
Sponsor Name:BIOVOMED | ||
Full Title: Evaluation of the immunogenicity and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine (PCV) in children primed with 2 doses of either GSK’s 10-valent PCV or Pfizer’s 13... | ||
Medical condition: To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 11-12 months of age in s... | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: SK (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001224-19 | Sponsor Protocol Number: 1/0196/16 | Start Date*: 2019-02-11 | ||||||||||||||||||||||||||
Sponsor Name:Lekárska fakulta Univerzity Komenského v Bratislave | ||||||||||||||||||||||||||||
Full Title: Non-invasive in-vivo prediction of therapeutic response to inhibitors of angiogenesis using gallium (68Ga) NODAGA-RGD PET/CT | ||||||||||||||||||||||||||||
Medical condition: Advanced metastatic cancer of the colon or rectum | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: SK (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002606-39 | Sponsor Protocol Number: 20162020 | Start Date*: 2016-11-09 | |||||||||||
Sponsor Name:Nemocnice Na Homolce | |||||||||||||
Full Title: Resurgence in sternotomy fortified by vitamin D supplementation in cardiac surgery | |||||||||||||
Medical condition: sternotomy healing | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004736-79 | Sponsor Protocol Number: 1102-CT02 | Start Date*: 2007-03-06 |
Sponsor Name:Antisense Therapeutics Ltd. | ||
Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje... | ||
Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-003932-23 | Sponsor Protocol Number: ML19387 | Start Date*: 2005-09-27 |
Sponsor Name:Roche spol. s r.o. | ||
Full Title: An Open-Label, Multicenter Phase IV Study assessing safety and efficacy of ribavirin (Copegus®) as part of combination therapy with peginterferon alfa-2a (Pegasys®) in selected groups of patients w... | ||
Medical condition: Otevřená, multicentrická studie fáze IV hodnotící bezpečnost a účinnost ribavirinu (Copegus®) v kombinované léčbě s peginterferonem alfa-2a (Pegasys®) u vybraných skupin pacientů s chronickou virov... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-005199-90 | Sponsor Protocol Number: RHB-104-04 | Start Date*: 2019-02-14 | |||||||||||
Sponsor Name:RedHill Biopharma Ltd. | |||||||||||||
Full Title: An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn’s Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study | |||||||||||||
Medical condition: Moderately to Severely Active Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001270-33 | Sponsor Protocol Number: GCTSK003 | Start Date*: 2015-07-28 | |||||||||||
Sponsor Name:Národný onkologický ústav | |||||||||||||
Full Title: A treatment strategy of the Use of 1st line Chemotherapy in Patients with Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors based on tumor marker decline: A Phase II Trial of paclitaxel... | |||||||||||||
Medical condition: Disseminated Non-Seminomatous Germ Cell Tumors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001958-10 | Sponsor Protocol Number: IMUNOR-201301 | Start Date*: 2013-09-04 | |||||||||||
Sponsor Name:ImunomedicA, a.s. | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-controlled, Multicenter, Phase III Confirmatory Study Assessing Efficacy and Safety of the IMUNOR Therapy Versus Placebo in Children with Recurrent ... | |||||||||||||
Medical condition: Recurrent Respiratory Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000534-36 | Sponsor Protocol Number: PR 1903 | Start Date*: 2004-09-13 |
Sponsor Name:Laboratoires Expanscience | ||
Full Title: Efficacy and Safety of Piascledine 300 versus Chondroitin Sulfate in a 6 Months Treatment plus 2 Months Observation in Patients with Osteoarthritis of the Knee | ||
Medical condition: Osteoarthritis of the Knee | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) HU (Completed) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-003421-17 | Sponsor Protocol Number: CL3-20098-051 | Start Date*: 2009-02-18 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: Efficacy and safety of agomelatine (25 mg/day with potential blinded adjustment at 50 mg/day) for 12 weeks in non-depressed out-patients with Generalized Anxiety Disorder. A 12-week randomised, dou... | |||||||||||||
Medical condition: Generalized Anxiety Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000687-27 | Sponsor Protocol Number: CLIC477D2303E01 | Start Date*: 2004-11-19 |
Sponsor Name:Novartis Pharma AG | ||
Full Title: A 52 week open-label extension study to evaluate the safety and tolerability of licarbazepine 750-2500 mg/d in the treatment of manic episodes of bipolar I disorder | ||
Medical condition: Bipolar I disorder, manic and mixed episodes DSM-IV criteria 296.0, 296.4 or 296.6 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: AT (Prematurely Ended) SK (Prematurely Ended) CZ (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2005-000549-13 | Sponsor Protocol Number: VX04-702-301 | Start Date*: 2005-05-03 |
Sponsor Name:Vertex Pharmaceuticals Incorporated | ||
Full Title: A 12-Week, Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study of Two Doses of VX-702 in Subjects with Moderate to Severe Rheumatoid Arthritis | ||
Medical condition: rheumatoid arthritis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-002711-25 | Sponsor Protocol Number: 039SC04253 | Start Date*: 2005-08-01 | |||||||||||
Sponsor Name:ANGELINI | |||||||||||||
Full Title: DOSE-FINDING STUDY OF TRAZODONE IN THE TREATMENT OF PATIENTS WITH PRIMARY INSOMNIA | |||||||||||||
Medical condition: TREATMENT OF THE INSOMNIA | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) SK (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022736-37 | Sponsor Protocol Number: Z7202L02 | Start Date*: 2011-02-09 | |||||||||||
Sponsor Name:Zambon S.p.A. | |||||||||||||
Full Title: Efficacy, tolerability and safety of Z7202, a once daily Diclofenac Diethylamine (DEA) medicated plaster in comparison with Flector®, a twice daily Diclofenac Hydroxyethylpyrrolidine medicated plas... | |||||||||||||
Medical condition: Diagnosis of single localized post-traumatic painful condition | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-006067-31 | Sponsor Protocol Number: NTI-ASP-0503 | Start Date*: 2008-04-04 |
Sponsor Name:Neurobiological Technologies Inc | ||
Full Title: ASP II (Ancrod Stroke Program) Study of Acute Viprinex™ for Emergency Stroke: A Randomized, Double-Blind, Placebo-Controlled Study of Ancrod (Viprinex™) in Subjects Beginning Treatment within 6 Hou... | ||
Medical condition: Acute Ischemic Stroke | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Prematurely Ended) AT (Prematurely Ended) SK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2014-003084-37 | Sponsor Protocol Number: SLU01 | Start Date*: 2014-10-15 | |||||||||||
Sponsor Name:SOTIO a.s. | |||||||||||||
Full Title: A phase I/II study to evaluate safety and efficacy of DCVAC/LuCa added to standard first line chemotherapy with carboplatin and paclitaxel +/- immune enhancers (interferon-α and hydroxychloroquine)... | |||||||||||||
Medical condition: Stage IV Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001264-38 | Sponsor Protocol Number: MOU-2017-01 | Start Date*: 2017-10-16 |
Sponsor Name:Masaryk Memorial Cancer Institute | ||
Full Title: Sequential FDG-PET and Plasma/Tissue miRNA as a Biomarkers of Preoperative Treatment Strategy in Locally Advanced Oesophago-Gastric Cancer | ||
Medical condition: locally advanced resectable oesophago-gastric adenocarcinoma (Siewert I – III) with T3N0, T4N0, T2 – T4N+, stage Ib – IIIc | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) SK (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005761-12 | Sponsor Protocol Number: SPD426-406 | Start Date*: 2013-05-06 | |||||||||||
Sponsor Name:Shire Development LLC | |||||||||||||
Full Title: A Phase 4, Randomized, Double-blind, Placebo-controlled, Crossover Study to Investigate the Clinical Benefit of Midodrine Hydrochloride in Male and Female Subjects with Symptomatic Orthostatic Hypo... | |||||||||||||
Medical condition: Symptomatic orthostatic hypotension (SOH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-000508-15 | Sponsor Protocol Number: L00023 GE 404 | Start Date*: 2005-10-06 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Efficacy and safety assessment of 6 months (24 weeks) treatment with Structum® 500 mg capsule bid in hip osteoarthritis: multicenter randomised double blind parallel group and placebo controlled st... | |||||||||||||
Medical condition: Patients with osteoarthritis of the hip | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
